Trials - GoINPHARMA
Friday, 14 December 2018 - 0:50

Trials

Gilead reports new data on efficacy of CAR-T therapy Yescarta

Gilead has reported results from ZUMA-1 clinical trial, designed to assess the breakthrough investigational therapy Yescarta (axicabtagene ciloleucel), on patients with large B-cell lymphoma. The treatment has been developed by Kite, the biotech acquired by Gilead in 2017. The trial…

Excellent Phase III results for Vertex’s new cystic fibrosis therapy

Boston, US-based Vertex Pharmaceuticals today has announced extremely positive results from two Phase III clinical trials assessing VX-659 on patients with cystic fibrosis. The results show that patients treated with VX-659 have lung functionality improved by 14% and good therapy…

New positive clinical results from ViiV’s (GSK) two-drug HIV therapy

ViiV, a subsidiary of GSK’s, yesterday evening announced results from the Phase III clinical trial Flair, assessing the efficacy of its two-drug (cabotegravir, rilpivirine) therapy on HIV patients. Specifically, the results show that the two-drug regime has the same efficacy…

Plastic fragments in human intestine

Researcher Philipp Schwalb, from the Medicine Department at the University of Vienna, has reported at the 26th United European Gastroenterology Week in Vienna the results of a study on individuals in whose intestine plastic micro-fragments had been found. Specifically, the…

Positive clinical results from AstraZeneca’s Lynparza (ovarian cancer)

AstraZeneca’s PR department doesn’t stop, neither on Sunday–this afternoon, it issued a release announcing that cancer drug Lynparza (PARP inhibitor) has shown efficacy on women with newly-diagnosed ovarian carcinoma. Specifically, scientists from the Britain-based group have introduced at the European…

Agreement on combo immunotherapy between Bristol-Myers Squibb and Compugen

US-based multinational Bristol-Myers Squibb (BMS) yesterday announced it plans to invest $12m in shares of the Israel-based biotech Compugen, in order to fund the clinical trials of investigational drug COM701, which will be tested in combination with immunotherapy Opdivo. Through…

Bausch Health announces good Phase III results from psoriasis therapy

Bausch Health–formerly known as Valeant–yesterday reported on a press release that the Journal of Drugs in Dermatology has published results from as many as two Phase III clinical trials, assessing corticosteroid Bryhali (halobetasol propionate) Lotion, 0.01% in patients with psoriasis….

Good Phase III results for Regeneron and Sanofi’s Dupixent

Regeneron Pharmaceuticals and Sanofi have announced at the  27th European Academy of Dermatology and Venereology (EADV) Congress, in Paris, positive results from a Phase III clinical trial assessing Dupixent (dupilumab) on adolescents with atopic dermatitis. The study was conducted on…

Excellent Phase III results for Gilead-Galapagos’ Filgotinib

Gilead announced yesterday, after trading had closed, that its investigational therapy Filgotinib (JAK-1 inhibitor), developed and licensed by Belgian biotech Galapagos, has reached all its primary and secondary endpoints in the early stages of the Phase III clinical trial Fitch-2….

Everything in place for first clinical trial with CRISPR technology

US-based biotech Vertex Pharmaceuticals, in partnership with Crispr Therapeutics, has started recruiting patients for the Phase I/II clinical trial with a treatment developed by the same Crispr Therapeutics–CTX001–for the treatment of beta-thalassemia. The FDA trial will be conducted in Regensburg…

Good Phase III results for Novartis’ cancer drug (breast cancer)

Novartis has announced today that its investigational BYL719  (alpelisib) therapy has reached its primary endpoints in the Phase III Solar-1 clinical trial. BYL719 is an alpha-specific PI3K inhibitor developed for the treatment of PIK3CA-mutant breast cancer, tested as intravenous infusion…

Excellent Phase III results from Zogenix (epilepsy), shares rise 30% in 2 days

California-based Zogenix has announced results from its Phase III Study 1504 clinical trial, designed to assess its investigational therapy ZX008 (fenfluramine hydrochloride), for the treatment of patients with Dravet syndrome, a rare form of epilepsy characterized by severe convulsive seizures….

Gilead-Galapagos’ Filgotinib shows efficacy in treating psoriatic arthritis

Gilead Sciences and Belgium-based biotech Galapagos yesterday announced, after Wall Street closed, data from the Phase II EQUATOR trial assessing filgotinib on 131 patients with psoriatic arthritis. The results are positive and demonstrate that filgotinib improves patients’ conditions after as…

Roche’s Tecentriq extends life expectancy of patients with lung cancer (NSCLC)

Switzerland-based Roche some hours ago announced results from the Phase III IMpower130 clinical trial, conducted on patients with non-squamous, non-small cell lung cancer (NSCLC) with Tecentriq (atezolizumab) vs conventional chemotherapy. The trial has shown that Roche’s therapy significantly increases patients’…

Hawaii bans some sunscreens as harmful for coral reefs

The Hawaii Government has passed a bill banning sunscreens containing Oxybenzone and Octinoxate, since these components are lethal for corals in seabed and in reefs. Approximately 6,000 pounds of sunscreen are deposited into the sea and may harm the fragile balance…

Genetics study on hair color origin and meaning

The scientific journal Nature Genetics has published an article reporting the results of a study performed by researchers Pirro G. Hysi and Ana M. Valdes, from King’s College London, on 300,000 people’s DNA, aimed at determining the genetic origins of…